← Russell 3000 cross-section

SIBN SI-BONE, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$878m
Revenue TTM
$214m
Net income TTM
$-15m
Free cash flow
$-4m
Composite score
44.2
Sector rank
#2091

Valuation

P / E
EV / EBITDA
EV / sales
4.1
FCF yield
-0.50%
Earnings yield vs 10-yr
-6.39pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6.8%
EBITDA margin
-5.3%
ROE
-8.0%
ROIC
-9.6%
Revenue growth
15.3%

Insider activity, last 90 days

Net open-market
$-3.25m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The CODMs use revenue and net loss at the consolidated level to measure segment profit and loss, allocate resources, monitor plan versus actual results, and manage operations. International revenue accounted for less than 10% of the total revenue during the periods presented. We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force and sales agents in other countries. During the six months ended June 30, 2026, we spent $9.4 million on research and development, equating to 8.7% of our revenue. …SI-BONE, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →